Developer docs
API playgroundTry for free, no card

Search company profiles

Mercury Bio

Full company profile

uuid0000wl5

Namestring
Mercury Bio
Legal namestring
Mercury Bio
Websiteurl
mercurybio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Mercury Bio is a preclinical, private biotechnology company developing intracellular immunotherapeutics using a proprietary drug delivery platform called yEV (yeast extracellular vesicle). The platform is built on engineered yeast-derived exosomes that are designed to cross the blood-brain barrier, penetrate target cells, escape endosomal degradation, and deliver large therapeutic cargo — including proteins, nanobodies, RNA, and small-molecule drugs — directly into the neuronal cytoplasm. MB-TIP (Targeting Intracellular Pathologies) is the therapeutic framework formalized around the platform in January 2026, integrating engineered nanobodies, AI-informed ligand design (developed in collaboration with Los Alamos National Laboratory), and engineered immunotherapeutics.

The company's lead therapeutic programs target Alzheimer's and Parkinson's diseases, where disease-modifying therapies have historically been limited by the inability of biologics to reach intracellular disease drivers inside neurons. The platform is also positioned for use in oncology, regenerative medicine, metabolic disease, and viral applications, and the company has entered an exclusive license with Frame Bio to apply yEV to bone and collagen regenerative therapeutics.

Mercury Bio monetizes through B2B licensing deals, joint development agreements, and academic research collaborations. Revenue is presently limited to research collaboration funding, licensing development fees, and milestone payments (e.g., Frame Bio, Himed, LANL/NCGR/UNM/UTMB consortium), with a Series A financing launched in early 2026 to fund IND-enabling work. The company is headquartered in Santa Fe, New Mexico, employs 1-10 people, and was rebranded from Spartina Biotechnologies in 2022.

Short descriptiontext

Mercury Bio is a preclinical biotechnology company developing the proprietary yEV yeast-exosome delivery platform and MB-TIP framework to deliver proteins, nanobodies, RNA, and small molecules into neurons for neurodegenerative and other diseases, monetizing via licensing and partnerships with pharmaceutical and biotech buyers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSanta Fe, United States
HQ citystring
Santa Fe
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug delivery platform, extracellular vesicle therapeutics, blood-brain barrier delivery, intracellular immunotherapeutics, neurodegenerative disease treatment
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology Drug Delivery Platforms
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Revenue
TypeLicensing Royalties
Description

Mercury Bio licenses its yEV platform technology to pharmaceutical and biotechnology companies for development of therapeutics. Under licensing agreements like the Frame Bio deal, Mercury Bio receives development fees against research milestones and licensing fee percentages for commercialized products.

mercurybio.com
2Joint Development Agreements
TypeProfessional Services
Description

The company enters joint development agreements with biotech and pharma companies to evaluate and develop new drug candidates using the yEV delivery platform, generating research funding and milestone payments.

mercurybio.com
3Research Collaborations
TypeProfessional Services
Description

Collaborative research projects with academic and institutional partners (LANL, NCGR, universities) provide technical assistance funding and support platform development while generating non-dilutive funding.

mercurybio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Mercury Bio develops and licenses a proprietary yeast-derived extracellular vesicle (yEV) drug delivery platform that transports proteins, nanobodies, RNA, and small-molecule therapeutics across the blood-brain barrier into neuronal cytoplasm while avoiding endosomal degradation. The platform underpins MB-TIP, a therapeutic framework currently advancing preclinical candidates for Alzheimer's and Parkinson's disease, with broader applications in oncology, regenerative, metabolic, and viral indications. Revenue is generated through licensing deals, joint development agreements, and research collaborations with pharmaceutical, biotechnology, and academic partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successfully delivered FLAG-peptide nanobodies to neurons across blood-brain barrier via IV administration in murine models
+2 more records
Product overview1 text field

Mercury Bio is an intracellular immunotherapeutic biotechnology company developing precision medicines designed to treat disease at its origin—inside the cell. The company's core technology is the yEV™ (yeast Extracellular Vesicle) platform, a proprietary drug delivery system based on bioengineered yeast-derived exosomes. This platform is the foundation for MB-TIP™ (Mercury Bio - Targeting Intracellular Pathologies), which integrates three core capabilities: targeted intracellular access via engineered nanobodies, AI modeling-informed precision targeting for ligand design, and engineered immunotherapeutics for candidate optimization. The company is initially focused on neurodegenerative diseases—Alzheimer's and Parkinson's—where intracellular dysfunction drives disease progression. The platform also supports therapeutic programs in oncology, regenerative medicine, metabolic diseases, and viral applications.

Product and service4 records
1yEV™ (Yeast Extracellular Vesicle) Platform
CategoryDrug Delivery Platform
Description

A proprietary drug delivery platform based on bioengineered yeast-derived extracellular vesicles (exosomes) that enables targeted intracellular delivery of proteins, nanobodies, RNA, and small-molecule drugs across the blood-brain barrier into neurons, avoiding endosomal degradation. Licensed to pharmaceutical and biotechnology partners.

2MB-TIP™ (Mercury Bio – Targeting Intracellular Pathologies)
CategoryTherapeutic Framework
Description

A therapeutic framework founded on the yEV platform that integrates three core capabilities: targeted intracellular access via engineered nanobodies, precision targeting through AI modeling-informed ligand design, and engineered immunotherapeutics for candidate identification and optimization. Designed to treat neurodegenerative diseases such as Alzheimer's and Parkinson's.

3Alzheimer's Disease Program
CategoryTherapeutic Program
Description

Preclinical-stage development of intracellular immunotherapeutics for Alzheimer's disease, targeting intracellular neuronal pathology including toxic protein aggregation and mitochondrial dysfunction using the yEV/MB-TIP platform.

4Parkinson's Disease Program
CategoryTherapeutic Program
Description

Preclinical-stage development of intracellular immunotherapeutics for Parkinson's disease, targeting intracellular pathology in neurons that drives progressive loss of function using the yEV/MB-TIP platform.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierSignificantTypeOthersAnnounced on2026-05-05
Description

Founding member of coalition of 21 biotechnology companies developing national innovation roadmap for sustaining U.S. biotech leadership. Alliance addresses declining public investment, capital market volatility, regulatory complexity, and global competition. Mercury Bio CEO serves on alliance board.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Strategic collaboration to accelerate development of CNS therapeutics for Parkinson's and Alzheimer's diseases. Combines Mercury Bio's yEV technology with Meta-Flux's AI-powered disease simulation platform for improved target selection, pathway prioritization, and development decision-making. The partnership addresses fundamental challenges in neurodegenerative disease drug development including blood-brain barrier crossing and intracellular pathway targeting.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Preclinical research collaboration conducting studies on yEV-mediated delivery of proteins to neurons across the blood-brain barrier. Simerly Lab used confocal microscopy to demonstrate abundant intracellular delivery of nanobodies to neurons in murine models, validating platform capabilities.

4Frame Bio
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-09-17
Description

Exclusive licensing agreement allowing Frame Bio to utilize the yEV platform for developing regenerative therapeutics for bone and collagen diseases and disorders. Frame Bio will develop bone regeneration therapies incorporating yEV technology with hydroxyapatite and collagen regeneration therapies. Mercury Bio receives development fees against research milestones and licensing fee percentages for commercialized products.

mercurybio.com
5Los Alamos National Laboratory
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-23
Description

Multi-partner research collaboration building on established CRADA agreement. LANL scientists collaborate with Mercury Bio on controlled studies of yEV technology for delivering large molecule drugs to diverse cell types. Project includes development of computational modeling system for AI-enabled membrane-attached targeting ligand design.

mercurybio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-23
Description

Research partnership for testing and advancing yEV technology in delivering therapeutic cargo to various cell and tissue types. NCGR contributes technical expertise and analytical capabilities to the multi-faceted biomolecular research project.

Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2024-07-23
Description

Research collaboration with UNM HSC as part of multi-partner Southwest consortium advancing yEV technology for delivery of therapeutic molecules to targeted cells.

Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2024-07-23
Description

Research partnership with UTMB contributing analytical capabilities and technical expertise to the multi-partner biomolecular research project testing yEV platform for diverse therapeutic cargo delivery.

Strategic tierSignificantTypeOthersAnnounced on2024-01-23
Description

Charter membership in leading global organization dedicated to advancing mRNA and next-generation encoding RNA therapeutics. CSO Richard Sayre serves on AMM board. Provides scientific contributions, networking, and shared vision with other leading biotechs, pharma companies, and academic institutions.

Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2023-07-13
Description

Joint R&D and licensing agreement to develop osteogenic materials for orthopedic applications including bone cements and implantable device coatings. Mercury Bio's yEV technology delivers BMP-9 and other osteogenic proteins into Himed's calcium phosphate scaffolds for controlled release to promote bone healing and growth.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical-stage biotech with a broad neurodegeneration pipeline built around proprietary BBB-crossing delivery technologies (e.g., ATV platform) and enzyme replacement strategies. A broader, better-capitalized incumbent in the same CNS delivery space.

TypeEmerging player
Description

Clinical-stage in vivo gene editing company developing LNP-based delivery of base and prime editors to the liver and other tissues. Comparable as an emerging player pushing novel delivery modalities into the clinic, with similar scientific and capital challenges.

TypeDirect peer
Description

UK-based biotech developing engineered extracellular vesicles (exosomes) for intracellular delivery of RNA, protein, and gene therapies across biological barriers including the BBB. The closest direct competitor to Mercury Bio's yEV platform in target product profile and therapeutic focus.

TypeBroad incumbent
Description

Commercial-stage leader in RNAi therapeutics with proprietary GalNAc and LNP delivery platforms for intracellular delivery of nucleic acids. A benchmark for what successful intracellular delivery franchises look like at scale.

TypeOthers
Description

Public biopreservation tools and services provider (NASDAQ: BLFS) connected to Mercury Bio via its Chairman Dana Barnard's prior exit and board member Mike Rice. Indirectly comparable as an enabling ecosystem participant for cell and gene therapy developers.

6Codiak BioSciences
TypeDirect peer
Description

Pioneer of engineered exosome therapeutics (engEx platform) for oncology and other indications. Highly comparable to Mercury Bio's yEV platform in terms of engineered extracellular vesicle approach, even though the company has substantially wound down its pipeline.

TypeBroad incumbent
Description

Large commercial-stage mRNA therapeutics company whose LNP-based delivery technology is the dominant benchmark for nucleic-acid intracellular delivery. While not vesicle-based, it defines partner expectations and competitive pressure on any novel delivery platform.

TypeRegional player
Description

CNS-focused biopharma developing therapeutics for neurological diseases (depression, epilepsy, neurodegeneration). Comparable as a focused CNS therapeutics developer, although it does not compete in intracellular delivery and operates with a wholly different modality.

9Aruna Bio
TypeDirect peer
Description

Developer of exosome-based therapeutics focused on CNS indications, including crossing the BBB to deliver nucleic acids and proteins into neurons. Closely comparable to Mercury Bio in both modality (exosomes) and therapeutic area (neurodegeneration).

TypeDirect peer
Description

Clinical-stage biotech developing extracellular vesicle-based therapeutics (including exosome platforms such as Capricor's StealthX) for neurological and inflammatory indications. Directly comparable as a vesicle-based delivery company advancing toward the clinic.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mercury Bio

Biotechnology Drug Delivery Platformsmercurybio.com

Mercury Bio is a preclinical biotechnology company developing the proprietary yEV yeast-exosome delivery platform and MB-TIP framework to deliver proteins, nanobodies, RNA, and small molecules into neurons for neurodegenerative and other diseases, monetizing via licensing and partnerships with pharmaceutical and biotech buyers.

What Mercury Bio does

Mercury Bio is a preclinical, private biotechnology company developing intracellular immunotherapeutics using a proprietary drug delivery platform called yEV (yeast extracellular vesicle). The platform is built on engineered yeast-derived exosomes that are designed to cross the blood-brain barrier, penetrate target cells, escape endosomal degradation, and deliver large therapeutic cargo — including proteins, nanobodies, RNA, and small-molecule drugs — directly into the neuronal cytoplasm. MB-TIP (Targeting Intracellular Pathologies) is the therapeutic framework formalized around the platform in January 2026, integrating engineered nanobodies, AI-informed ligand design (developed in collaboration with Los Alamos National Laboratory), and engineered immunotherapeutics.

The company's lead therapeutic programs target Alzheimer's and Parkinson's diseases, where disease-modifying therapies have historically been limited by the inability of biologics to reach intracellular disease drivers inside neurons. The platform is also positioned for use in oncology, regenerative medicine, metabolic disease, and viral applications, and the company has entered an exclusive license with Frame Bio to apply yEV to bone and collagen regenerative therapeutics.

Mercury Bio monetizes through B2B licensing deals, joint development agreements, and academic research collaborations. Revenue is presently limited to research collaboration funding, licensing development fees, and milestone payments (e.g., Frame Bio, Himed, LANL/NCGR/UNM/UTMB consortium), with a Series A financing launched in early 2026 to fund IND-enabling work. The company is headquartered in Santa Fe, New Mexico, employs 1-10 people, and was rebranded from Spartina Biotechnologies in 2022.

Mercury Bio firmographics

Firmographics
Name
Mercury Bio
Legal name
Mercury Bio
Website
https://mercurybio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Mercury Bio is a preclinical biotechnology company developing the proprietary yEV yeast-exosome delivery platform and MB-TIP framework to deliver proteins, nanobodies, RNA, and small molecules into neurons for neurodegenerative and other diseases, monetizing via licensing and partnerships with pharmaceutical and biotech buyers.
Ownership category
akta.pro rank

Mercury Bio industry classification

Industry
Product category
Biotechnology Drug Delivery Platforms
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Drug delivery platform
  • Extracellular vesicle therapeutics
  • Blood-brain barrier delivery
  • Intracellular immunotherapeutics
  • Neurodegenerative disease treatment

Where Mercury Bio is headquartered

Location

Headquarters

HQ city
Santa Fe
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mercury Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing Revenue: Mercury Bio licenses its yEV platform technology to pharmaceutical and biotechnology companies for development of therapeutics. Under licensing agreements like the Frame Bio deal, Mercury Bio receives development fees against research milestones and licensing fee percentages for commercialized products.
  2. Joint Development Agreements: The company enters joint development agreements with biotech and pharma companies to evaluate and develop new drug candidates using the yEV delivery platform, generating research funding and milestone payments.
  3. Research Collaborations: Collaborative research projects with academic and institutional partners (LANL, NCGR, universities) provide technical assistance funding and support platform development while generating non-dilutive funding.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Mercury Bio product offering

Product offering

Core offering

Mercury Bio develops and licenses a proprietary yeast-derived extracellular vesicle (yEV) drug delivery platform that transports proteins, nanobodies, RNA, and small-molecule therapeutics across the blood-brain barrier into neuronal cytoplasm while avoiding endosomal degradation. The platform underpins MB-TIP, a therapeutic framework currently advancing preclinical candidates for Alzheimer's and Parkinson's disease, with broader applications in oncology, regenerative, metabolic, and viral indications. Revenue is generated through licensing deals, joint development agreements, and research collaborations with pharmaceutical, biotechnology, and academic partners.

Product overview

Mercury Bio is an intracellular immunotherapeutic biotechnology company developing precision medicines designed to treat disease at its origin—inside the cell. The company's core technology is the yEV™ (yeast Extracellular Vesicle) platform, a proprietary drug delivery system based on bioengineered yeast-derived exosomes. This platform is the foundation for MB-TIP™ (Mercury Bio - Targeting Intracellular Pathologies), which integrates three core capabilities: targeted intracellular access via engineered nanobodies, AI modeling-informed precision targeting for ligand design, and engineered immunotherapeutics for candidate optimization. The company is initially focused on neurodegenerative diseases—Alzheimer's and Parkinson's—where intracellular dysfunction drives disease progression. The platform also supports therapeutic programs in oncology, regenerative medicine, metabolic diseases, and viral applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • yEV™ (Yeast Extracellular Vesicle) Platform A proprietary drug delivery platform based on bioengineered yeast-derived extracellular vesicles (exosomes) that enables targeted intracellular delivery of proteins, nanobodies, RNA, and small-molecule drugs across the blood-brain barrier into neurons, avoiding endosomal degradation. Licensed to pharmaceutical and biotechnology partners.
  • MB-TIP™ (Mercury Bio – Targeting Intracellular Pathologies) A therapeutic framework founded on the yEV platform that integrates three core capabilities: targeted intracellular access via engineered nanobodies, precision targeting through AI modeling-informed ligand design, and engineered immunotherapeutics for candidate identification and optimization. Designed to treat neurodegenerative diseases such as Alzheimer's and Parkinson's.
  • Alzheimer's Disease Program Preclinical-stage development of intracellular immunotherapeutics for Alzheimer's disease, targeting intracellular neuronal pathology including toxic protein aggregation and mitochondrial dysfunction using the yEV/MB-TIP platform.
  • Parkinson's Disease Program Preclinical-stage development of intracellular immunotherapeutics for Parkinson's disease, targeting intracellular pathology in neurons that drives progressive loss of function using the yEV/MB-TIP platform.

Quantifiable outcome

  • Successfully delivered FLAG-peptide nanobodies to neurons across blood-brain barrier via IV administration in murine models
  • +2 more outcomes

Companies that use Mercury Bio

Customer profile

Segments3 records

Ideal customer profiles2 records

Mercury Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Mercury Bio partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered significant and core.

  • American Biotech Innovation Alliance (ABIA)significantOthers · 5 May 2026Founding member of coalition of 21 biotechnology companies developing national innovation roadmap for sustaining U.S. biotech leadership. Alliance addresses declining public investment, capital market volatility, regulatory complexity, and global competition. Mercury Bio CEO serves on alliance board.
  • Meta-FluxcoreStrategic or Co-development Partner · 18 December 2025Strategic collaboration to accelerate development of CNS therapeutics for Parkinson's and Alzheimer's diseases. Combines Mercury Bio's yEV technology with Meta-Flux's AI-powered disease simulation platform for improved target selection, pathway prioritization, and development decision-making. The partnership addresses fundamental challenges in neurodegenerative disease drug development including blood-brain barrier crossing and intracellular pathway targeting.
  • Vanderbilt University School of Medicine (Simerly Lab)coreStrategic or Co-development Partner · 1 October 2025Preclinical research collaboration conducting studies on yEV-mediated delivery of proteins to neurons across the blood-brain barrier. Simerly Lab used confocal microscopy to demonstrate abundant intracellular delivery of nanobodies to neurons in murine models, validating platform capabilities.
  • Frame BiocoreOEM/ Whitelabel/ Licensing Partner · 17 September 2025Exclusive licensing agreement allowing Frame Bio to utilize the yEV platform for developing regenerative therapeutics for bone and collagen diseases and disorders. Frame Bio will develop bone regeneration therapies incorporating yEV technology with hydroxyapatite and collagen regeneration therapies. Mercury Bio receives development fees against research milestones and licensing fee percentages for commercialized products.
  • Los Alamos National LaboratorycoreStrategic or Co-development Partner · 23 July 2024Multi-partner research collaboration building on established CRADA agreement. LANL scientists collaborate with Mercury Bio on controlled studies of yEV technology for delivering large molecule drugs to diverse cell types. Project includes development of computational modeling system for AI-enabled membrane-attached targeting ligand design.
  • National Center for Genome Resources (NCGR)coreStrategic or Co-development Partner · 23 July 2024Research partnership for testing and advancing yEV technology in delivering therapeutic cargo to various cell and tissue types. NCGR contributes technical expertise and analytical capabilities to the multi-faceted biomolecular research project.
  • University of New Mexico Health Sciences CentersignificantStrategic or Co-development Partner · 23 July 2024Research collaboration with UNM HSC as part of multi-partner Southwest consortium advancing yEV technology for delivery of therapeutic molecules to targeted cells.
  • University of Texas Medical BranchsignificantStrategic or Co-development Partner · 23 July 2024Research partnership with UTMB contributing analytical capabilities and technical expertise to the multi-partner biomolecular research project testing yEV platform for diverse therapeutic cargo delivery.
  • Alliance for mRNA MedicinessignificantOthers · 23 January 2024Charter membership in leading global organization dedicated to advancing mRNA and next-generation encoding RNA therapeutics. CSO Richard Sayre serves on AMM board. Provides scientific contributions, networking, and shared vision with other leading biotechs, pharma companies, and academic institutions.
  • HimedsignificantStrategic or Co-development Partner · 13 July 2023Joint R&D and licensing agreement to develop osteogenic materials for orthopedic applications including bone cements and implantable device coatings. Mercury Bio's yEV technology delivers BMP-9 and other osteogenic proteins into Himed's calcium phosphate scaffolds for controlled release to promote bone healing and growth.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Mercury Bio competitors and assessment

Company assessment

Broad incumbents

  • Denali Therapeutics: Clinical-stage biotech with a broad neurodegeneration pipeline built around proprietary BBB-crossing delivery technologies (e.g., ATV platform) and enzyme replacement strategies. A broader, better-capitalized incumbent in the same CNS delivery space.
  • Alnylam Pharmaceuticals: Commercial-stage leader in RNAi therapeutics with proprietary GalNAc and LNP delivery platforms for intracellular delivery of nucleic acids. A benchmark for what successful intracellular delivery franchises look like at scale.
  • Moderna: Large commercial-stage mRNA therapeutics company whose LNP-based delivery technology is the dominant benchmark for nucleic-acid intracellular delivery. While not vesicle-based, it defines partner expectations and competitive pressure on any novel delivery platform.

Emerging players

  • Verve Therapeutics: Clinical-stage in vivo gene editing company developing LNP-based delivery of base and prime editors to the liver and other tissues. Comparable as an emerging player pushing novel delivery modalities into the clinic, with similar scientific and capital challenges.

Direct peers

  • Evox Therapeutics: UK-based biotech developing engineered extracellular vesicles (exosomes) for intracellular delivery of RNA, protein, and gene therapies across biological barriers including the BBB. The closest direct competitor to Mercury Bio's yEV platform in target product profile and therapeutic focus.
  • Codiak BioSciences: Pioneer of engineered exosome therapeutics (engEx platform) for oncology and other indications. Highly comparable to Mercury Bio's yEV platform in terms of engineered extracellular vesicle approach, even though the company has substantially wound down its pipeline.
  • Aruna Bio: Developer of exosome-based therapeutics focused on CNS indications, including crossing the BBB to deliver nucleic acids and proteins into neurons. Closely comparable to Mercury Bio in both modality (exosomes) and therapeutic area (neurodegeneration).
  • Capricor Therapeutics: Clinical-stage biotech developing extracellular vesicle-based therapeutics (including exosome platforms such as Capricor's StealthX) for neurological and inflammatory indications. Directly comparable as a vesicle-based delivery company advancing toward the clinic.

Others

  • BioLife Solutions: Public biopreservation tools and services provider (NASDAQ: BLFS) connected to Mercury Bio via its Chairman Dana Barnard's prior exit and board member Mike Rice. Indirectly comparable as an enabling ecosystem participant for cell and gene therapy developers.

Regional players

  • Sage Therapeutics: CNS-focused biopharma developing therapeutics for neurological diseases (depression, epilepsy, neurodegeneration). Comparable as a focused CNS therapeutics developer, although it does not compete in intracellular delivery and operates with a wholly different modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Mercury Bio social profiles

Digital presence

Mercury Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mercury Bio leadership team

Management profile

Number of profiles

Profiles15 records

Mercury Bio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mercury Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mercury Bio

What does Mercury Bio do?

Mercury Bio develops and licenses a proprietary yeast-derived extracellular vesicle (yEV) drug delivery platform that transports proteins, nanobodies, RNA, and small-molecule therapeutics across the blood-brain barrier into neuronal cytoplasm while avoiding endosomal degradation. The platform underpins MB-TIP, a therapeutic framework currently advancing preclinical candidates for Alzheimer's and Parkinson's disease, with broader applications in oncology, regenerative, metabolic, and viral indications. Revenue is generated through licensing deals, joint development agreements, and research collaborations with pharmaceutical, biotechnology, and academic partners.

Is Mercury Bio a public or private company?

Mercury Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mercury Bio founded?

Mercury Bio was founded in 2022. It employs 11 to 50 people.

Where is Mercury Bio based?

Mercury Bio is headquartered in Santa Fe, United States, in the North America region.

How does Mercury Bio make money?

Three revenue lines are on record. Licensing Revenue is the primary driver. The others are joint Development Agreements and research Collaborations.

Who are Mercury Bio's main competitors?

Broad incumbents on record are Denali Therapeutics, Alnylam Pharmaceuticals and Moderna. Verve Therapeutics is listed as an emerging player. Direct peers are Evox Therapeutics, Codiak BioSciences, Aruna Bio and Capricor Therapeutics. BioLife Solutions is listed as an others. Sage Therapeutics is listed as a regional player.

Does Mercury Bio have an API?

No public API is recorded for Mercury Bio.

What industry is Mercury Bio in?

Mercury Bio's product category is Biotechnology Drug Delivery Platforms. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournMercury Bio Promotes Casey Perkins to Chief Business OfficerMercury Bio announced the promotion of Cassandra 'Casey' Perkins to Chief Business Officer, effective June 22, 2026, following her December 2025 hire where she led business development and corporate strategy. Perkins brings over 25 years of leadership experience in biotech and pharmaceuticals, with expertise in commercial strategy, market access, and cell and gene therapies across neurology, oncology, and immunology. She was recently recognized by CIO Views Magazine as one of the Top 10 Empowering Women Leaders to Follow in 2026 and is a founding member of the American Biotech Innovation Alliance.PR NewswireMercury Bio Launches MB-TIP™--Revolutionizing Immunotherapy with Intracellular TargetingMercury Bio Inc. announced the launch of MB-TIP™, a proprietary exosome-based technology platform using yEV™ to deliver large proteins, nanobodies, and RNA directly into neurons for treating neurodegenerative diseases such as Alzheimer's and Parkinson's. Preclinical models in 2025 demonstrated successful blood-brain barrier crossing and direct cytoplasmic delivery without endosomal degradation, positioning the candidates for upcoming FDA IND applications. The company has also launched a Series A financing round and will present the technology next week at the Biotech Showcase in San Francisco.ParkinsonsnewstodayTech duo to advance brain-penetrating drugs for CNS disordersMercury Bio and Meta-Flux have announced a collaboration to develop large-molecule therapeutics capable of crossing the blood-brain barrier to treat neurological conditions, starting with Parkinson's and Alzheimer's diseases. The partnership combines Mercury Bio's yeast extracellular vesicle technology for delivering therapeutic molecules into nerve cells with Meta-Flux's AI platform that uses biological and clinical data to model disease states and predict drug effects. The collaboration aims to overcome a key challenge in neurology drug development, as most molecules cannot effectively penetrate the blood-brain barrier to reach target sites in the brain.PR NewswireMercury Bio and Meta-Flux Announce Strategic Collaboration to Advance Large-Molecule Therapeutics for Parkinson's and Alzheimer's DiseasesMercury Bio and Meta-Flux announced a strategic collaboration to accelerate the development of large-molecule therapeutics for Parkinson's and Alzheimer's diseases. The partnership combines Mercury Bio's yeast extracellular vesicle technology with Meta-Flux's AI-powered disease simulation platform to improve target selection and early decision-making for central nervous system disorders.PR NewswireMercury Bio Announces Appointment of Casey Perkins as Vice President of Corporate Strategy & Business DevelopmentMercury Bio announced the appointment of Cassandra "Casey" Perkins as Vice President of Corporate Strategy & Business Development, bringing over 25 years of biotech and pharmaceutical leadership experience including commercialization of therapies like ZOLGENSMA. Perkins will lead corporate strategy and business development, focusing on strategic partnerships and investor relations as the company advances its yEV™ intracellular drug-delivery platform. The appointment comes after the company shared pre-clinical research in October demonstrating successful delivery of proteins into neurons across the blood-brain barrier in murine models, suggesting potential new pathways for treating neurological disorders like Alzheimer's and Parkinson's.PR NewswireMercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein Cargo to the BrainMercury Bio announced positive preclinical results showing its yEV™ yeast exosome-based drug delivery platform successfully delivered nanobody proteins into neurons across the blood-brain barrier in a murine model study conducted at Vanderbilt University School of Medicine. The study, using confocal microscopy, demonstrated specific intracellular delivery to neurons with limited distribution to other brain cells, representing a rare non-invasive approach for crossing the BBB where 98% of small-molecule drugs and nearly 100% of biologics are typically rejected. The findings could open new therapeutic pathways for treating neurological diseases like Alzheimer's and Parkinson's.PR NewswireFrame Bio Licenses Novel Drug Delivery Technology from Mercury Bio to Develop Regenerative Therapies for Bone and Collagen Diseases and DisordersFrame Bio, a biotechnology company focused on structural diseases, announced an exclusive licensing agreement with Mercury Bio to access Mercury Bio's novel extracellular vesicle drug encapsulation platform (yEV™) for developing regenerative therapeutics. Under the agreement, Frame Bio will use the technology to create bone regeneration therapies incorporating hydroxyapatite and BMP-2 proteins, as well as collagen regeneration therapies, with both programs remaining in pre-clinical phases for the coming year. Mercury Bio will receive development fees tied to research milestones and licensing fee percentages for any products that reach commercial markets.PR NewswireMercury Bio Announces Biomolecular Research Project to Include Los Alamos National Laboratory, the National Center for Genome Resources, the University of New Mexico, and the University of Texas MedicMercury Bio announced a strategic collaboration with Los Alamos National Laboratory, the National Center for Genome Resources, the University of New Mexico Health Sciences Center, and the University of Texas Medical Branch to accelerate research on its yEV™ drug delivery platform. The platform aims to deliver therapeutic cargos including mRNA, nucleic acids, enzymes, and antibodies to various cell and tissue types for treating multiple pathologies. The CEO stated the multi-partner collaboration represents a major step forward in demonstrating the safety and efficacy of delivering nucleic acids to targeted cells for next-generation RNA therapeutics.American City Business JournalsStartups to Watch: Mercury Bio ready to scale biomolecular drug delivery platformMercury Bio, a Santa Fe-based startup, emerged from stealth in August 2023 with a biomolecular drug delivery platform called yEV. It has raised about $4.5 million and plans to raise $20 million in 2024, with one commercial deal in progress and negotiations with seven parties.PR NewswireMercury Bio Welcomes New Finance Director & Closes $2M Early Funding RoundMercury Bio closed a $2 million seed funding round and appointed John Tomes as Finance Director in August 2023. The company plans to initiate a Series A investment round following investor interest gained from presenting its yEV technology at an mRNA therapeutics conference.